APOBEC3G Contributes to HIV-1 Variation through Sublethal Mutagenesis

被引:139
作者
Sadler, Holly A. [1 ,2 ]
Stenglein, Mark D. [1 ,3 ,5 ]
Harris, Reuben S. [1 ,3 ,5 ]
Mansky, Louis M. [1 ,2 ,4 ]
机构
[1] Univ Minnesota, Inst Mol Virol, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Dept Diagnost & Biol Sci, Sch Dent, Minneapolis, MN 55455 USA
[3] Univ Minnesota, Dept Biochem Mol Biol & Biophys, Sch Med, Minneapolis, MN 55455 USA
[4] Univ Minnesota, Dept Microbiol, Sch Med, Minneapolis, MN 55455 USA
[5] Univ Minnesota, Ctr Genome Engn, Minneapolis, MN 55455 USA
基金
美国国家卫生研究院;
关键词
IMMUNODEFICIENCY-VIRUS TYPE-1; REVERSE TRANSCRIPTION; CYTIDINE DEAMINASES; MUTATIONAL ANALYSIS; DRUG-RESISTANCE; ENZYME APOBEC3G; POOL IMBALANCES; VIF PROTEIN; VIRAL-RNA; IN-VIVO;
D O I
10.1128/JVI.00056-10
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The mammalian APOBEC3 proteins are an important component of the cellular innate immune response to retroviral infection. APOBEC3G can extinguish HIV-1 infectivity by its incorporation into virus particles and subsequent cytosine deaminase activity that attacks the nascent viral cDNA during reverse transcription, causing lethal mutagenesis. It has been suggested, but not formally shown, that APOBEC3G can also induce sublethal mutagenesis, which would maintain virus infectivity and contribute to HIV-1 variation. To test this, we developed a novel model system utilizing an HIV-1 vector and a panel of APOBEC3G-expressing cells. We observed proviruses with single APOBEC3G-mediated mutations (in the presence or absence of Vif), occurring at distinct hot spots and which could be rescued and shown to have infectivity. These data indicate that APOBEC3G-dependent restriction of HIV-1 can result in viable viral progeny that harbor sublethal levels of G-to-A mutations. Such mutations have the potential to contribute significantly to HIV-1 evolution, pathogenesis, immune escape, and drug resistance.
引用
收藏
页码:7396 / 7404
页数:9
相关论文
共 46 条
  • [11] VPR IS REQUIRED FOR EFFICIENT REPLICATION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 IN MONONUCLEAR PHAGOCYTES
    CONNOR, RI
    CHEN, BK
    CHOE, S
    LANDAU, NR
    [J]. VIROLOGY, 1995, 206 (02) : 935 - 944
  • [12] Role of the human T-cell leukemia virus type 1 PTAP motif in Gag targeting and particle release
    Dorweiler, IJ
    Ruone, SJ
    Wang, H
    Burry, RW
    Mansky, LM
    [J]. JOURNAL OF VIROLOGY, 2006, 80 (07) : 3634 - 3643
  • [13] A new reporter cell line to monitor HIV infection and drug susceptibility in vitro
    Gervaix, A
    West, D
    Leoni, LM
    Richman, DD
    WongStaal, F
    Corbeil, J
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (09) : 4653 - 4658
  • [14] HIV-I Vif, APOBEC, and intrinsic immunity
    Goila-Gaur, Ritu
    Strebel, Klaus
    [J]. RETROVIROLOGY, 2008, 5 (1)
  • [15] The interaction of APOBEC3G with human immunodeficiency virus type 1 nucleocapsid inhibits tRNA3Lys annealing to viral RNA
    Guo, Fei
    Cen, Shan
    Niu, Meijuan
    Yang, Yiliang
    Gorelick, Robert J.
    Kleiman, Lawrence
    [J]. JOURNAL OF VIROLOGY, 2007, 81 (20) : 11322 - 11331
  • [16] Inhibition of tRNALys3-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replicationv
    Guo, Fei
    Cen, Shan
    Niu, Meijuan
    Saadatmand, Jenan
    Kleiman, Lawrence
    [J]. JOURNAL OF VIROLOGY, 2006, 80 (23) : 11710 - 11722
  • [17] Evolution of HIV-1 isolates that use a novel Vif-independent mechanism to resist restriction by human APOBEC3G
    Hache, Guylaine
    Shindo, Keisuke
    Albin, John S.
    Harris, Reuben S.
    [J]. CURRENT BIOLOGY, 2008, 18 (11) : 819 - 824
  • [18] Haché G, 2006, AIDS REV, V8, P148
  • [19] DNA determination mediates innate immunity to retroviral infection
    Harris, RS
    Bishop, KN
    Sheehy, AM
    Craig, HM
    Petersen-Mahrt, SK
    Watt, IN
    Neuberger, MS
    Malim, MH
    [J]. CELL, 2003, 113 (06) : 803 - 809
  • [20] HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 VIRAL-PROTEIN-R (VPR) ARRESTS CELLS IN THE G(2) PHASE OF THE CELL-CYCLE BY INHIBITING P34(CDC2) ACTIVITY
    HE, JL
    CHOE, S
    WALKER, R
    DIMARZIO, P
    MORGAN, DO
    LANDAU, NR
    [J]. JOURNAL OF VIROLOGY, 1995, 69 (11) : 6705 - 6711